Vegetable Signature From Human Metabolomics Responses

Dietary Intervention Studies on a Variety of Vegetables

The purpose of this study is to perform dietary intervention studies on a variety of vegetables.

Study Overview

Detailed Description

Plant-based foods have always been an important component of a healthy diet. High intake of plant foods may not only maintain normal bodily functions through the provision of dietary fiber, vitamins, and minerals but also relieve symptoms and prevent diseases. Many studies have pointed out that high intake of plant foods may reduce the incidence of non-communicable disease. Past research investigating the effect of phytochemicals has usually been limited to single substances or single foods. However, a number of researchers have pointed out that phytonutrients and dietary components are likely to act synergistically.Health effects and mechanisms of phytonutrients in combination have not been carefully studied in population settings. The technology of metabolomics has enabled the simultaneous measurement of hundreds of small molecules in biological samples. Exploring the change of metabolites after feeding can not only help us understand the role of plant foods, but may also provide opportunities to assess plant food intake levels.

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • BMI 18.5~30 kg/m2
  • non-smoker
  • non-alcoholic

Exclusion Criteria:

  • Unwilling to stop taking the dietary supplements that may affect the experiment result.
  • Unwilling to take the provided meal during the designated period.
  • Taking hypertension or diabetes drugs.
  • Diagnosed immune diseases (such as allergic diseases, autoimmune diseases, etc.), liver diseases, metabolic diseases (such as hyperthyroidism or hypothyroidism), or other not suitable for the dietary study.
  • Diagnosed cancer or other severe diseases.
  • Suffered from urinary tract infection or took antibiotic in the past three months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Control
Participants were fed a standardized diet (without any vegetables) in this experiment.
A standardized diet without any vegetables was provided.
EXPERIMENTAL: Spinach
Participants were fed a standardized diet with 200g spinach in this experiment.
A standardized diet with 200g spinach was provided.
EXPERIMENTAL: Celery
Participants were fed a standardized diet with 200g celery in this experiment.
A standardized diet with 200g celery was provided.
EXPERIMENTAL: Onion
Participants were fed a standardized diet with 200g onion in this experiment.
A standardized diet with 200g onion was provided.
EXPERIMENTAL: Mixed Vegetables
Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intensities of multiple serum metabolites
Time Frame: Baseline (fasting state before breakfast at 7:30AM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
Baseline (fasting state before breakfast at 7:30AM)
Intensities of multiple serum metabolites
Time Frame: 4 Hours (immediately before lunch at 11:30AM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
4 Hours (immediately before lunch at 11:30AM)
Intensities of multiple serum metabolites
Time Frame: 5.5 hours (after lunch at 13:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
5.5 hours (after lunch at 13:00PM)
Intensities of multiple serum metabolites
Time Frame: 6.5 hours (after lunch at 14:00 PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
6.5 hours (after lunch at 14:00 PM)
Intensities of multiple serum metabolites
Time Frame: 7.5 hours (after lunch at 15:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
7.5 hours (after lunch at 15:00PM)
Intensities of multiple serum metabolites
Time Frame: 8.5 hours (after lunch at 16:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
8.5 hours (after lunch at 16:00PM)
Intensities of multiple serum metabolites
Time Frame: 9.5 hours (after lunch at 17:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
9.5 hours (after lunch at 17:00PM)
Intensities of multiple serum metabolites
Time Frame: 10.5 hours (after lunch at 18:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
10.5 hours (after lunch at 18:00PM)
Intensities of multiple serum metabolites
Time Frame: 11.5 hours (after lunch at 19:00PM)
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
11.5 hours (after lunch at 19:00PM)
Intensities of multiple urinary metabolites
Time Frame: Baseline (overnight urine sample collected at 7:30AM)
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
Baseline (overnight urine sample collected at 7:30AM)
Intensities of multiple urinary metabolites
Time Frame: 3.5~4 hours (before lunch urine sample collected during 11:00~11:30AM)
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
3.5~4 hours (before lunch urine sample collected during 11:00~11:30AM)
Intensities of multiple urinary metabolites
Time Frame: 4.5~6.5 hours (2-hour after lunch urine sample collected from 12:00 to 14:00PM)
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
4.5~6.5 hours (2-hour after lunch urine sample collected from 12:00 to 14:00PM)
Intensities of multiple urinary metabolites
Time Frame: 6.5~8.5 hours (4-hour after lunch urine sample collected from 14:00 to 16:00PM)
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
6.5~8.5 hours (4-hour after lunch urine sample collected from 14:00 to 16:00PM)
Intensities of multiple urinary metabolites
Time Frame: 8.5~11.5 hours (7-hour after lunch urine sample collected from 16:00 to 19:00PM)
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment. Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
8.5~11.5 hours (7-hour after lunch urine sample collected from 16:00 to 19:00PM)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 11, 2011

Primary Completion (ACTUAL)

December 31, 2012

Study Completion (ACTUAL)

May 28, 2015

Study Registration Dates

First Submitted

January 31, 2018

First Submitted That Met QC Criteria

March 28, 2018

First Posted (ACTUAL)

March 30, 2018

Study Record Updates

Last Update Posted (ACTUAL)

March 30, 2018

Last Update Submitted That Met QC Criteria

March 28, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Control

3
Subscribe